Annika Schaefer

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5873186/publications.pdf

Version: 2024-02-01

35 papers	2,837 citations	201674 27 h-index	361022 35 g-index
36 all docs	36 docs citations	36 times ranked	4428 citing authors

#	Article	IF	Citations
1	Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer. Lancet, The, 2022, 399, 905-907.	13.7	60
2	Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer. Cancer Cell, 2022, 40, 114-116.	16.8	50
3	COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety. Nature Reviews Clinical Oncology, 2022, 19, 385-401.	27.6	135
4	Spatial patterns of tumour growth impact clonal diversification in a computational model and the TRACERx Renal study. Nature Ecology and Evolution, 2022, 6, 88-102.	7.8	30
5	Selection of metastasis competent subclones in the tumour interior. Nature Ecology and Evolution, 2021, 5, 1033-1045.	7.8	50
6	Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2. Nature Medicine, 2021, 27, 1362-1366.	30.7	70
7	Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. Nature Cancer, 2021, 2, 1321-1337.	13.2	66
8	Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. Nature Cancer, 2021, 2, 1305-1320.	13.2	123
9	Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. Cancer Cell, 2021, 39, 1497-1518.e11.	16.8	126
10	Cancer, COVID-19, and Antiviral Immunity: The CAPTURE Study. Cell, 2020, 183, 4-10.	28.9	40
11	Identification of miR-21-5p and miR-210-3p serum levels as biomarkers for patients with papillary renal cell carcinoma: a multicenter analysis. Translational Andrology and Urology, 2020, 9, 1314-1322.	1.4	10
12	Circular RNAs and Their Linear Transcripts as Diagnostic and Prognostic Tissue Biomarkers in Prostate Cancer after Prostatectomy in Combination with Clinicopathological Factors. International Journal of Molecular Sciences, 2020, 21, 7812.	4.1	8
13	Instability of circular RNAs in clinical tissue samples impairs their reliable expression analysis using RT-qPCR: from the myth of their advantage as biomarkers to reality. Theranostics, 2020, 10, 9268-9279.	10.0	12
14	Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue. Cell Reports, 2020, 31, 107550.	6.4	51
15	Inhibiting WNT and NOTCH in renal cancer stem cells and the implications for human patients. Nature Communications, 2020, 11, 929.	12.8	113
16	A Novel Predictor Tool of Biochemical Recurrence after Radical Prostatectomy Based on a Five-MicroRNA Tissue Signature. Cancers, 2019, 11, 1603.	3.7	28
17	Circular RNAs in Clear Cell Renal Cell Carcinoma: Their Microarray-Based Identification, Analytical Validation, and Potential Use in a Clinico-Genomic Model to Improve Prognostic Accuracy. Cancers, 2019, 11, 1473.	3.7	37
18	miR-9-5p in Nephrectomy Specimens is a Potential Predictor of Primary Resistance to First-Line Treatment with Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell Carcinoma. Cancers, 2018, 10, 321.	3.7	18

#	Article	IF	Citations
19	Circular RNAs: a new class of biomarkers as a rising interest in laboratory medicine. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1992-2003.	2.3	23
20	The translational potential of microRNAs as biofluid markers of urological tumours. Nature Reviews Urology, 2016, 13, 734-752.	3.8	104
21	Diagnostic and prognostic potential of circulating cell-free genomic and mitochondrial DNA fragments in clear cell renal cell carcinoma patients. Clinica Chimica Acta, 2016, 452, 109-119.	1.1	52
22	Piwi-interacting RNAs as novel prognostic markers in clear cell renal cell carcinomas. Journal of Experimental and Clinical Cancer Research, 2015, 34, 61.	8.6	90
23	MicroRNA Signature Helps Distinguish Early from Late Biochemical Failure in Prostate Cancer. Clinical Chemistry, 2013, 59, 1595-1603.	3.2	50
24	The Antiapoptotic Function of miR-96 in Prostate Cancer by Inhibition of FOXO1. PLoS ONE, 2013, 8, e80807.	2.5	69
25	MicroRNAs as New Diagnostic and Prognostic Biomarkers in Urological Tumors. Critical Reviews in Oncogenesis, 2013, 18, 289-302.	0.4	20
26	The miRNA-kallikrein axis of interaction: a new dimension in the pathogenesis of prostate cancer. Biological Chemistry, 2012, 393, 379-389.	2.5	31
27	MiR-133b Targets Antiapoptotic Genes and Enhances Death Receptor-Induced Apoptosis. PLoS ONE, 2012, 7, e35345.	2.5	87
28	miRNAs can predict prostate cancer biochemical relapse and are involved in tumor progression. International Journal of Oncology, 2011, 39, 1183-92.	3.3	34
29	Reference genes for the relative quantification of microRNAs in renal cell carcinomas and their metastases. Analytical Biochemistry, 2011, 417, 233-241.	2.4	78
30	MicroRNAs as Regulators of Signal Transduction in Urological Tumors. Clinical Chemistry, 2011, 57, 954-968.	3.2	113
31	Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. International Journal of Cancer, 2010, 126, 1166-1176.	5.1	518
32	Suitable reference genes for relative quantification of miRNA expression in prostate cancer. Experimental and Molecular Medicine, 2010, 42, 749.	7.7	96
33	MicroRNAs and cancer: Current state and future perspectives in urologic oncology. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 4-13.	1.6	76
34	Diagnostic, prognostic and therapeutic implications of microRNAs in urologic tumors. Nature Reviews Urology, 2010, 7, 286-297.	3.8	93
35	Robust MicroRNA Stability in Degraded RNA Preparations from Human Tissue and Cell Samples. Clinical Chemistry, 2010, 56, 998-1006.	3.2	275